GSK plc reports

Company location
London
GSK plc has filed 6,820 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 376-400 of 1,000 matching filings.

Per page
25
Current page
16
6-K File 001-15170

GSKS SHINGRIX FULLY LIQUID FDA APPROVAL

Filing date
17 Jul 2025
Reporting date
17 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
17 Jul 2025
Reporting date
17 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
16 Jul 2025
Reporting date
16 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Jul 2025
Reporting date
15 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
15 Jul 2025
Reporting date
15 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Jul 2025
Reporting date
14 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA

Filing date
14 Jul 2025
Reporting date
14 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
14 Jul 2025
Reporting date
14 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
11 Jul 2025
Reporting date
11 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
10 Jul 2025
Reporting date
10 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
09 Jul 2025
Reporting date
09 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
08 Jul 2025
Reporting date
08 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD

Filing date
07 Jul 2025
Reporting date
07 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
07 Jul 2025
Reporting date
07 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
07 Jul 2025
Reporting date
07 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
03 Jul 2025
Reporting date
03 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
02 Jul 2025
Reporting date
02 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Jul 2025
Reporting date
01 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
01 Jul 2025
Reporting date
01 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
30 Jun 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
27 Jun 2025
Reporting date
27 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
26 Jun 2025
Reporting date
26 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
25 Jun 2025
Reporting date
25 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
24 Jun 2025
Reporting date
24 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR DECLARATION

Filing date
24 Jun 2025
Reporting date
24 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .